SCHEMBL1330072

SCHEMBL1330072

Cc1cccc(NC(=O)Nc2ccc(-c3ccc4c(-c5ccccc5)n[nH]c4c3)cc2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.75
NTRK1 P04629 3/20 0.62
FLT3 P36888 6/20 0.59
CSF1R P07333 5/20 0.59
FLT1 P17948 5/20 0.59
KIT P10721 5/20 0.59
FLT4 P35916 4/20 0.59
AURKA O14965 4/20 0.59
LCK P06239 3/20 0.59
ROCK2 O75116 3/20 0.59
RPS6KA3 P51812 3/20 0.59
AURKB Q96GD4 3/20 0.59
RPS6KB1 P23443 2/20 0.59
STK3 Q13188 2/20 0.59
ROCK1 Q13464 2/20 0.59
PLK3 Q9H4B4 2/20 0.59
SGK2 Q9HBY8 2/20 0.59
PLK4 O00444 2/20 0.59
DYRK1A Q13627 2/20 0.59
NTRK2 Q16620 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331383 0.89 KDR (0.72) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1330844 0.87 KDR (0.69) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1331347 0.87 KDR (0.69) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL423310 0.87 KDR (0.73) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1331628 0.86 KDR (0.66) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1331629 0.86 KDR (0.66) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1331714 0.86 KDR (0.70) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1332041 0.85 KDR (0.69) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1331624 0.84 KDR (0.71) KDRNTRK1FLT3CSF1RFLT1
SCHEMBL1329799 0.84 KDR (0.66) KDRNTRK1FLT3CSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569301-A1 INDAZOLE INHIBITORS OF KINASE Abbvie Inc. (US) 2013-03-20 EP disclosed
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
WO-2011143430-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 WO disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB KDR 11/4885NTRK1 805/4885FLT3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.